Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CASP1 | P29466 | 2/20 | 0.36 |
| ▸ | CASP4 | P49662 | 1/20 | 0.36 |
| ▸ | CASP5 | P51878 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL564259 | 0.98 | CASP1 (0.37) | CYP1A2CASP1CASP4CASP5HRH4 | |
| SCHEMBL5102077 | 0.82 | ALDH1A1 (0.43) | CYP1A2CASP1CASP4CASP5HRH4 | |
| SCHEMBL2363290 | 0.67 | CHKA (0.40) | SMN1; SMN2KDM4EGAAALDH1A1MAPT | |
| SCHEMBL14812759 | 0.67 | IP6K1 (0.36) | CYP1A2CASP1CASP4CASP5HRH4 | |
| SCHEMBL6643440 | 0.67 | — | — | |
| SCHEMBL4665338 | 0.65 | — | — | |
| SCHEMBL2424620 | 0.64 | HPGD (0.44) | SMN1; SMN2GAAALDH1A1MAPTHPGD | |
| SCHEMBL4019264 | 0.64 | CASP1 (0.45) | CYP1A2CASP1CASP4CASP5HRH4 | |
| SCHEMBL2992722 | 0.64 | CYP1A2 (0.42) | CYP1A2CASP1CASP4CASP5HRH4 | |
| SCHEMBL6577700 | 0.64 | HRH4 (0.39) | CYP1A2CASP1CASP4CASP5HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046288-A1 | Hydrazonamide Compounds That Modulate Hsp90 Activity | Synta Pharmacueticals Corp. | 2012-02-23 | — | — | US | claimed |
| US-6936711-B2 | Process for preparation of penam derivatives from cepham derivatives | ORCHID CHEMICALS AND PHARMACEUTICALS LIMITED (US) | 2005-08-30 | — | — | US | claimed |
| US-10889553-B2 | Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same | NYSNOBIO IRELAND DAC (IE) | 2021-01-12 | — | — | US | disclosed |
| US-20200172497-A1 | ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | NYSNOBIO IRELAND DAC (IE) | 2020-06-04 | — | — | US | disclosed |
| US-8163730-B2 | Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-04-24 | — | — | US | disclosed |
| EP-2061452-B1 | ANTI CANCER USE OF CAFFEIC ACID AND DERIVATIVES | PIRAMAL LIFE SCIENCES LTD (IN) | 2011-10-26 | — | — | EP | disclosed |
| US-7964631-B2 | Fused tricyclic compounds as inhibitors of tumor necrosis factor-α | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | disclosed |
| US-20100324026-A1 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-12-23 | — | — | US | disclosed |
| US-20100305094-A1 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-12-02 | — | — | US | disclosed |
| US-7834052-B2 | Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-11-16 | — | — | US | disclosed |
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA (SE) | 2010-08-26 | — | — | US | disclosed |
| US-20090281099-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ANDRES-GIL JOSE IGNACIO | 2009-11-12 | — | — | US | disclosed |
| EP-2061452-A2 | ANTI CANCER USE OF CAFFEIC ACID AND DERIVATIVES | Piramal Life Sciences Limited (IN) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008026125-A2 | ANTI CANCER USE OF CAFFEIC ACID AND DERIVATIVES | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008020203-A1 | PYRIDINYLQUINAZ0LINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | WO | disclosed |
| US-20070299050-A1 | Fused Tricyclic Compounds as Inhibitors of Tumor Necrosis Factor-Alpha | NICHOLAS PIRAMAL INDIA LIMITED. (IN) | 2007-12-27 | — | — | US | disclosed |
| EP-1812419-A2 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA | Nicholas Piramal India Limited (IN) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006051477-A2 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2006-05-18 | — | — | WO | disclosed |
| EP-1523484-A2 | 3-PHENYL ANALOGS OF TOXOFLAVINE AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-04-20 | — | — | EP | disclosed |
| WO-2004007498-A2 | 3-PHENYL ANALOGS OF TOXOFLAVINE AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324026-A1 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA | CD40, TNFRSF1A, OXER1 | CYP1A2 852/4885CASP1 755/4885CASP4 206/4885 |
| US-20070299050-A1 | Fused Tricyclic Compounds as Inhibitors of Tumor Necrosis Factor-Alpha | CD40, TNFRSF1A, OXER1 | CYP1A2 1004/4885CASP1 683/4885CASP4 184/4885 |
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | CYP1A2 1115/4885CASP1 1615/4885CASP4 3343/4885 |
| US-20090281099-A1 | SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS A MEDICINE | ADRA2C, CHRNA5, ADRB2 | CYP1A2 145/4885CASP1 4289/4885CASP4 4332/4885 |
| US-20120046288-A1 | Hydrazonamide Compounds That Modulate Hsp90 Activity | HSP90AB1, HSP90AA1, HSP90AB2P | CYP1A2 2726/4885CASP1 3662/4885CASP4 4175/4885 |
| US-20200172497-A1 | ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | ATG7, PINK1, ADRM1 | CYP1A2 624/4885CASP1 1042/4885CASP4 2209/4885 |
| US-10889553-B2 | Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same | ATG7, PINK1, ADRM1 | CYP1A2 624/4885CASP1 1042/4885CASP4 2209/4885 |
| US-20100305094-A1 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF TUMOR NECROSIS FACTOR-ALPHA | CD40, TNFRSF1A, OXER1 | CYP1A2 1004/4885CASP1 683/4885CASP4 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.